A Review: A Comparative Study of Branded and Generic Anti-Hypertensive Drugs
DOI:
https://doi.org/10.22270/ajprd.v12i2.1359Keywords:
Keywords: Antihypertensive, Generic Drug, Branded drugAbstract
This comprehensive review investigates the market landscape of antihypertensive medications, undertaking a detailed comparative analysis of branded and generic options. In the face of rising global prevalence of hypertension, the study aims to provide a holistic perspective on the efficacy, safety, and market dynamics shaping the use of branded and generic drugs in the management of these chronic conditions.
Utilizing data derived from market trends, sales analytics, and consumer preferences, the review scrutinizes the market behaviors and forces influencing the adoption of branded and generic antihypertensive drugs. Factors such as cost-effectiveness, patient adherence, and healthcare provider preferences are explored to shed light on the complexities associated with medication selection in the context of chronic disease management.
Through an in-depth examination of industry strategies, regulatory frameworks, and the role of healthcare policies, the review aims to uncover the interplay between market dynamics and clinical considerations. It seeks to inform healthcare professionals, policymakers, and industry stakeholders about the evolving landscape of choices in antihypertensive therapies, fostering a nuanced understanding that can guide optimal decision-making in patient care and resource allocation.
Downloads
References
Prasad, Amit Mohan, Gautam Chakraborty, Sajjan Singh Yadav, and Salima Bhatia. "Addressing the social determinants of health through health system strengthening and inter-sectoral convergence: the case of the Indian National Rural Health Mission." Global health action 6, no. 1 (2013): 20135.
Bjerkedal,T.:Over weightand hypertension. Acta Med Scand159:13,1957.
a systematic analysis for the Global Burden of Disease Study 2016." Lancet (London, England)[Internet]. Elsevier 390 (2017): 1260-1344.
.Zhou, Bin, James Bentham, Mariachiara Di Cesare, Honor Bixby, Goodarz Danaei, Melanie J. Cowan, Christopher J. Paciorek et al. "Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19• 1 million participants." The Lancet 389, no. 10064 (2017): 37-55.
Rodgers, Anthony, Majid Ezzati, Stephen Vander Hoorn, Alan D. Lopez, Ruey-Bin Lin, Christopher J. L. Murray, and Group Comparative Risk Assessment Collaborating. "Distribution of major health risks: findings from the Global Burden of Disease study." PLoS medicine 1, no. 1 (2004):
https://www.healthline.com/health/types-and-stages-of-hypertension.
7.Moran, Andrew E., Michelle C. Odden, AnusornThanataveerat, Keane Y. Tzong, Petra W. Rasmussen, David Guzman, Lawrence Williams, Kirsten Bibbins-Domingo, Pamela G. Coxson, and Lee Goldman. "Cost-effectiveness of hypertension therapy according to 2014 guidelines." New England Journal of Medicine 372, no. 5 (2015): 447-455.
Banerji, Amit, and Maulana Azad. "Review of asia-pacific's healthcare systems with emphasis on the role of generic pharmaceuticals." Academy of Health Care Management Journal 9 (2013
Rathi, Komal, Preeti Kamboj, Priyanka Gupta Bansal, and G. S. Toteja. "A review of selected nutrition & health surveys in India." The Indian journal of medical research 148, no. 5 (2018): 596.
Prenissl, Jonas, Jennifer Manne-Goehler, Lindsay M. Jaacks, Dorairaj Prabhakaran, Ashish Awasthi, Anne Christine Bischops, Rifat Atun et al. "Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years." PLoS medicine 16, no. 5 (2019): e1002801.
Mathur P, Kulothungan V, Leburu S, et al. National noncommunicable disease monitoring survey (NNMS) in India: estimating risk factor prevalence in adult population. PLoS One. 2021;16(3):e0246712.
Price, Ceiling. "National Pharmaceutical Pricing Authority." paragraph 13, no. 2 (2013).
Woodcock J, Khan M, Yu LX. Withdrawal of generic budeprion for nonbioequivalence. N Engl J Med. 2012;367:2463–5. Perhaps the most recent example of official FDA actions that resulted in removal of a nonbioequivalent drug product from the US market.
14.Data, Exclusivity. "Orange book: approved drug products with therapeutic equivalence evaluations." (2017).
15..Kesselheim, Aaron S., Alexander S. Misono, Joy L. Lee, Margaret R. Stedman, M. Alan Brookhart, Niteesh K. Choudhry, and William H. Shrank. "Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis." Jama 300, no. 21 (2008): 2514-2526.
Kotwani, Anita, Margaret Ewen, Dalia Dey, Shobha Iyer, P. K. Lakshmi, Archana Patel, Kannamma Raman et al. "Prices & availability of common medicines at six sites in India using a standard methodology." Indian journal of medical research125, no. 5 (2007): 645-654.
Amit, Guy, Amit Rosen, Avraham B. Wagshal, Dan Y. Bonneh, Tzvika Liss, Aviva Grosbard, Reuven Ilia, and Amos Katz. "Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation." The American journal of cardiology 93, no. 12 (2004): 1558-1560.
Campbell, Eric G., Genevieve Pham-Kanter, Christine Vogeli, and Lisa I. Iezzoni. "Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians." JAMA internal medicine 173, no. 3 (2013): 237-239.
.A.H. Prabhakar, R. Giridhar, J. Pharm. Biomed. Anal., 2002, 27, 861.
Published
Versions
- 2024-04-15 (2)
- 2024-04-15 (1)
How to Cite
Issue
Section
Copyright (c) 2024 Anuksh Telrandhe, Ketakee Phadnis, Nilakshi Dhoble, Nitin Padole, Jagdish Baheti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.